OncoCyte Corporation (OCX): Price and Financial Metrics
OCX Stock Summary
- With a price/sales ratio of 325.38, OncoCyte Corp has a higher such ratio than 98.3% of stocks in our set.
- As for revenue growth, note that OCX's revenue has grown 664.78% over the past 12 months; that beats the revenue growth of 98.97% of US companies in our set.
- In terms of volatility of its share price, OCX is more volatile than 94.75% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to OncoCyte Corp are MOTS, DOMO, BGMD, EPAY, and VIVE.
- OCX's SEC filings can be seen here. And to visit OncoCyte Corp's official web site, go to www.oncocyte.com.
OCX Stock Price Chart Interactive Chart >
OCX Price/Volume Stats
| Current price | $4.30 | 52-week high | $6.57 |
| Prev. close | $4.45 | 52-week low | $1.15 |
| Day low | $4.23 | Volume | 215,058 |
| Day high | $4.49 | Avg. volume | 1,325,436 |
| 50-day MA | $5.11 | Dividend yield | N/A |
| 200-day MA | $2.81 | Market Cap | 382.33M |
OncoCyte Corporation (OCX) Company Bio
OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.
Latest OCX News From Around the Web
Below are the latest news stories about OncoCyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint InhibitorsIRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will host a key opinion leader (KOL) call on novel biomarkers in identifying appropriate responders to immune checkpoint inhibitors on Monday, April 19, 2021 at 11:30am Eastern Time. The event will feature a presentation by KOLs David Gandara, MD, UC Davis Comprehensive Cancer Center, and Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center, who will present an overview of the use and limitations of currently clinically available biomarkers, such as PD-L1 and tumor mutational burden (TMB), in identifying responders to immunotherapies, ... |
Oncocyte’s DetermaIO shows correlation with immunotherapy response in bladder cancerPresenting new data at AACR 2021 annual meeting, Oncocyte (OCX) says its DetermaIO test designed to predict response to immunotherapy demonstrated test performance in bladder cancer,The latest findings add to the predictive value shown in lung and breast cancers previously, the company said.The studies were intended to assess the ability of... |
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT IRVINE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, presented new data at the Ameri... |
Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare ConferenceIRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that management is scheduled to participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference. Presentation details:Date: April 14, 2021Time: 10:15am EDT The presentation will be accessible via a live webcast at https://wsw.com/webcast/needham107/ocx/2075172 Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com. About Oncocyte CorporationOncocyte is a molecular diagnostics company whose mission is to provide actionable answers at c... |
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial ResultsDetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection Scheduled to present data at 2021 American Association for Cancer Research (AACR) Annual Meeting that supports DetermaIO’s potential pan-cancer applicability Strengthened balance sheet to support ramping commercialization of Oncocyte’s broadening product portfolio Conference call scheduled for 4:30 P.M. EDT IRVINE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today reported financial results for the fourth quarter and full year 2020 ended D... |
OCX Price Returns
| 1-mo | -10.51% |
| 3-mo | 4.37% |
| 6-mo | 154.44% |
| 1-year | 95.45% |
| 3-year | 75.51% |
| 5-year | -28.33% |
| YTD | 79.92% |
| 2020 | 6.22% |
| 2019 | 63.04% |
| 2018 | -70.32% |
| 2017 | -34.04% |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...